| __timestamp | PTC Therapeutics, Inc. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 79838000 | 4167274 |
| Thursday, January 1, 2015 | 121816000 | 5247851 |
| Friday, January 1, 2016 | 117633000 | 4925118 |
| Sunday, January 1, 2017 | 4577000 | 14930297 |
| Monday, January 1, 2018 | 12670000 | 25371768 |
| Tuesday, January 1, 2019 | 12135000 | 23921274 |
| Wednesday, January 1, 2020 | 18942000 | 25338236 |
| Friday, January 1, 2021 | 32328000 | 20182966 |
| Saturday, January 1, 2022 | 44678000 | 17562000 |
| Sunday, January 1, 2023 | 65486000 | 25212000 |
Unlocking the unknown
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This chart provides a fascinating comparison between Pharming Group N.V. and PTC Therapeutics, Inc. over the past decade. From 2014 to 2023, PTC Therapeutics, Inc. has seen a significant fluctuation in its cost of revenue, peaking in 2015 with a 1,218% increase compared to Pharming Group N.V. In contrast, Pharming Group N.V. has demonstrated a more stable growth, with its cost of revenue increasing by approximately 500% from 2014 to 2023. Notably, 2017 marked a pivotal year for Pharming Group N.V., as its cost of revenue surpassed PTC Therapeutics, Inc. for the first time. This trend highlights the strategic shifts and operational efficiencies that can impact financial outcomes in the biotech sector.
Analyzing Cost of Revenue: Merck & Co., Inc. and Pharming Group N.V.
Cost of Revenue Trends: Pfizer Inc. vs PTC Therapeutics, Inc.
BeiGene, Ltd. vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: United Therapeutics Corporation vs PTC Therapeutics, Inc.
Cost of Revenue Comparison: Sarepta Therapeutics, Inc. vs Pharming Group N.V.
Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and Pharming Group N.V.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and PTC Therapeutics, Inc.
Analyzing Cost of Revenue: Pharming Group N.V. and Alkermes plc
Analyzing Cost of Revenue: Pharming Group N.V. and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Pharming Group N.V. and MiMedx Group, Inc.
Cost Insights: Breaking Down PTC Therapeutics, Inc. and Perrigo Company plc's Expenses
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Dyne Therapeutics, Inc.